^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Non Small Cell Lung Cancer
    Drug:MK-1084 (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

    Excerpt:
    ...- Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRAS G12C mutation who has received at least 1 line of therapy for systemic disease For Arm 2...
    Trial ID:
    NCT05067283
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    663P - Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC

    Published date:
    10/16/2023
    Excerpt:
    ORR was 19% (8/42 pts, all PR; 4 in CRC, 4 in NSCLC) in Arm 1 and 47% (7/15 pts, all PR) in Arm 2; 7 and 3 pts not yet assessed, respectively….MK-1084 as monotherapy and in combination with pembro showed manageable safety and preliminary antitumor activity in pts with previously treated solid malignancies and previously untreated NSCLC whose tumors harbored KRAS G12C mutations.
    Trial ID:
    NCT05067283